Literature DB >> 25972053

Prevalence and prediction of obstructive coronary artery disease in patients referred for valvular heart surgery.

Jason M Lappé1, Justin L Grodin1, Yuping Wu2, Corinne Bott-Silverman1, Leslie Cho3.   

Abstract

Current guidelines recommend a coronary evaluation before valvular heart surgery (VHS). Diagnostic coronary angiography is recommended in patients with known coronary artery disease (CAD) and those with high pretest probability of CAD. In patients with low or intermediate pretest probability of CAD, the guidelines recommend coronary computed tomographic angiography. However, there are no tools available to objectively assess a patient's risk for obstructive CAD before VHS. To address this deficit, 5,360 patients without histories of CAD who underwent diagnostic coronary angiography as part of preoperative evaluation for VHS were identified. Obstructive CAD was defined as ≥50% stenosis in ≥1 artery. Of the patients assessed, 1,035 (19.3%) were found to have obstructive CAD. Through multivariate analysis, age, gender, diabetes, renal dysfunction, hyperlipidemia, and a family history of premature CAD were found to be associated with the presence of obstructive CAD (p <0.001 for all). After adjustment, the specific dysfunctional valve was not associated with the presence of obstructive CAD. Patients were then randomly split into derivation and validation cohorts. Within the derivation cohort, using only age, gender, and the presence or absence of risk factors, a model was constructed to predict the risk for obstructive CAD (C statistic 0.766, 95% confidence interval 0.750 to 0.783). The risk prediction model performed well within the validation cohort (C statistic 0.767, 95% confidence interval 0.751 to 0.784, optimism 0.004). The bias-corrected C statistic for the model was 0.765 (95% confidence interval 0.748 to 0.782). In conclusion, this novel risk prediction tool can be used to objectively risk-stratify patients who undergo preoperative evaluation before VHS and to facilitate appropriate triage to computed tomographic angiography or diagnostic coronary angiography.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25972053     DOI: 10.1016/j.amjcard.2015.03.063

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Degenerative aortic valve disease and coronary artery disease are either side of a coin.

Authors:  Ramachandra Barik
Journal:  Indian Heart J       Date:  2016-01-12

2.  External validation and extension of a diagnostic model for obstructive coronary artery disease: a cross-sectional predictive evaluation in 4888 patients of the Austrian Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography (CARDIIGAN) cohort.

Authors:  Michael Edlinger; Maria Wanitschek; Jakob Dörler; Hanno Ulmer; Hannes F Alber; Ewout W Steyerberg
Journal:  BMJ Open       Date:  2017-04-07       Impact factor: 2.692

3.  Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic.

Authors:  Raúl Moreno; José-Luis Díez; José-Antonio Diarte; Pablo Salinas; José María de la Torre Hernández; Juan F Andres-Cordón; Ramiro Trillo; Juan Alonso Briales; Ignacio Amat-Santos; Rafael Romaguera; José-Francisco Díaz; Beatriz Vaquerizo; Soledad Ojeda; Ignacio Cruz-González; Daniel Morena-Salas; Armando Pérez de Prado; Fernando Sarnago; Pilar Portero; Alejandro Gutierrez-Barrios; Fernando Alfonso; Eduard Bosch; Eduardo Pinar; José-Ramón Ruiz-Arroyo; Valeriano Ruiz-Quevedo; Jesús Jiménez-Mazuecos; Fernando Lozano; José-Ramón Rumoroso; Enrique Novo; Francisco J Irazusta; Bruno García Del Blanco; José Moreu; Sara M Ballesteros-Pradas; Araceli Frutos; Manuel Villa; Eduardo Alegría-Barrero; Rosa Lázaro; Emilio Paredes
Journal:  Cardiovasc Diabetol       Date:  2021-03-23       Impact factor: 9.951

4.  Prevalence and Prediction of Obstructive Coronary Artery Disease in Patients Undergoing Primary Heart Valve Surgery.

Authors:  José Guilherme Cazelli; Gabriel Cordeiro Camargo; Dany David Kruczan; Clara Weksler; Alexandre Rouge Felipe; Ilan Gottlieb
Journal:  Arq Bras Cardiol       Date:  2017-09-28       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.